ES2537017T3 - Anticuerpo dirigido contra el receptor EP4 de la prostaglandina E2 humano - Google Patents

Anticuerpo dirigido contra el receptor EP4 de la prostaglandina E2 humano Download PDF

Info

Publication number
ES2537017T3
ES2537017T3 ES11829187.1T ES11829187T ES2537017T3 ES 2537017 T3 ES2537017 T3 ES 2537017T3 ES 11829187 T ES11829187 T ES 11829187T ES 2537017 T3 ES2537017 T3 ES 2537017T3
Authority
ES
Spain
Prior art keywords
receptor
directed against
antibody directed
human prostaglandin
prostaglandin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11829187.1T
Other languages
English (en)
Other versions
ES2537017T9 (es
Inventor
Kiyoshi Takayama
Tomoko Shimizu
Yuji Urushibata
Yukihiko Sugimoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NB HEALTH LAB CO Ltd
NB HEALTH LABORATORY Co Ltd
Original Assignee
NB HEALTH LAB CO Ltd
NB HEALTH LABORATORY Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NB HEALTH LAB CO Ltd, NB HEALTH LABORATORY Co Ltd filed Critical NB HEALTH LAB CO Ltd
Application granted granted Critical
Publication of ES2537017T3 publication Critical patent/ES2537017T3/es
Publication of ES2537017T9 publication Critical patent/ES2537017T9/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)

Abstract

Un anticuerpo monoclonal o un fragmento funcional del mismo, cada uno de los cuales se une al dominio extracelular de un receptor de PGE2 del subtipo EP4 e inhibe la función de dicho receptor EP4 de PGE2 de aumento del nivel intracelular de AMPc.
ES11829187.1T 2010-09-29 2011-09-28 Anticuerpo dirigido contra el receptor EP4 de la prostaglandina E2 humano Active ES2537017T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010218158 2010-09-29
JP2010218158 2010-09-29
PCT/JP2011/072190 WO2012043634A1 (ja) 2010-09-29 2011-09-28 ヒトプロスタグランジンｅ２受容体ｅｐ４に対する抗体

Publications (2)

Publication Number Publication Date
ES2537017T3 true ES2537017T3 (es) 2015-06-01
ES2537017T9 ES2537017T9 (es) 2015-08-21

Family

ID=45893073

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11829187.1T Active ES2537017T3 (es) 2010-09-29 2011-09-28 Anticuerpo dirigido contra el receptor EP4 de la prostaglandina E2 humano

Country Status (13)

Country Link
US (3) US9175080B2 (es)
EP (1) EP2623594B9 (es)
JP (1) JP5273689B2 (es)
KR (1) KR101857310B1 (es)
CN (2) CN103459595B (es)
AU (1) AU2011309028B2 (es)
CA (1) CA2812756C (es)
DK (1) DK2623594T5 (es)
ES (1) ES2537017T3 (es)
HK (1) HK1191378A1 (es)
IL (1) IL225447A (es)
NZ (1) NZ609887A (es)
WO (1) WO2012043634A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106632673A (zh) * 2015-11-01 2017-05-10 钮晓音 抗pge2单克隆抗体及其使用
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
CN106929477B (zh) * 2017-03-20 2020-01-10 江南大学 一株抗前列腺素F2α的特异性单克隆抗体杂交瘤细胞株WXX-2及其应用
CA3060394A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives as pge2 receptor modulators
WO2018210987A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as pge2 receptor modulators
US11446298B2 (en) 2017-05-18 2022-09-20 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
EP3625224B1 (en) 2017-05-18 2021-08-04 Idorsia Pharmaceuticals Ltd N-substituted indole derivatives
HUE056080T2 (hu) 2017-05-18 2022-01-28 Idorsia Pharmaceuticals Ltd Fenilszármazékok mint PGE2 receptor modulátorok
US11357787B2 (en) 2019-02-18 2022-06-14 Nb Health Laboratory Co., Ltd. Method for selecting cells, method for producing nucleic acid, method for producing recombinant cells, method for producing target substance, method for producing pharmaceutical composition, and reagent
GB2596803A (en) * 2020-07-06 2022-01-12 Petmedix Ltd Expression vector production & high-throughput cell screening
JPWO2022102731A1 (es) 2020-11-13 2022-05-19

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE9202892D0 (sv) 1992-10-02 1992-10-02 Kabi Pharmacia Ab Dna encoding a prostaglandin receptor, a host cell transformed therewith and an expression product thereof
US5605814A (en) 1993-08-31 1997-02-25 Merck Frosst Canada Inc. DNA encoding human prostaglandin receptor EP2
US6395878B1 (en) 1994-05-05 2002-05-28 Allergan Sales, Inc. Nucleic acid encoding a human EP prostaglandin receptor
CA2485485A1 (en) 2002-05-23 2003-12-04 Theratechnologies Inc. Antagonistic peptides of prostaglandin e2 receptor subtype ep4
CA2515081A1 (en) * 2003-02-07 2004-08-19 Protein Design Labs, Inc. Amphiregulin antibodies and their use to treat cancer and psoriasis
WO2004073589A2 (en) * 2003-02-24 2004-09-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep4 (prostaglandin e2 ep4)
SG192496A1 (en) * 2008-07-08 2013-08-30 Abbott Lab Prostaglandin e2 binding proteins and uses thereof
CN102170905B (zh) 2008-08-01 2016-08-03 阿克西斯股份有限公司 骨关节炎治疗剂及预防剂

Also Published As

Publication number Publication date
DK2623594T3 (da) 2015-05-18
CA2812756A1 (en) 2012-04-05
CN103459595B (zh) 2016-04-13
IL225447A0 (en) 2013-06-27
CN103459595A (zh) 2013-12-18
JP5273689B2 (ja) 2013-08-28
IL225447A (en) 2017-02-28
NZ609887A (en) 2015-01-30
DK2623594T5 (en) 2015-09-21
US20130197199A1 (en) 2013-08-01
ES2537017T9 (es) 2015-08-21
US20160075780A1 (en) 2016-03-17
US9175080B2 (en) 2015-11-03
US20190389949A1 (en) 2019-12-26
EP2623594A4 (en) 2013-11-13
JPWO2012043634A1 (ja) 2014-02-24
KR101857310B1 (ko) 2018-05-11
EP2623594B9 (en) 2015-07-22
AU2011309028B2 (en) 2016-03-17
KR20140027051A (ko) 2014-03-06
US11649281B2 (en) 2023-05-16
EP2623594A1 (en) 2013-08-07
US10435465B2 (en) 2019-10-08
CA2812756C (en) 2020-06-30
CN106046158A (zh) 2016-10-26
EP2623594B1 (en) 2015-02-25
HK1191378A1 (zh) 2014-07-25
WO2012043634A1 (ja) 2012-04-05
AU2011309028A1 (en) 2013-05-23

Similar Documents

Publication Publication Date Title
ES2537017T3 (es) Anticuerpo dirigido contra el receptor EP4 de la prostaglandina E2 humano
CR20140146A (es) Anticuerpos anti-cd134 (ox40) y usos de los mismos
PE20221007A1 (es) Anticuerpos anti-receptor de transferrina con afinidad disenada
ES2722300T3 (es) Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
MX2011011825A (es) Anticuerpos humanizados para axl.
CR20150618A (es) Anticuerpos receptores de antitransferina y métodos de uso
EA201101165A1 (ru) СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АКТИВНОСТЬ Toll-ПОДОБНЫХ РЕЦЕПТОРОВ
CO6280499A2 (es) Anticuerpos monoclonales, los cuales enlazan al dominio extracelular del receptor axl de tirosina quinasa y los cuales por lo menos parcialmente inhiben la actividad axl
RS54795B1 (sr) Anti-her3 antitela i njihova korišćenja
SV2011003880A (es) Anticuerpos humanos de alta afinidad para el receptor il-4 humano
CO6721041A2 (es) Anticuerpo anti-pcsk9 y métodos de uso
PE20150002A1 (es) Anticuerpos anti-fcrn
CO6720984A2 (es) Anticuerpos anti-mesotelina e inmunoconjugados
EA201270465A1 (ru) Новейшие модуляторы
EA201391540A1 (ru) Агонисты fgfr1 и способы их применения
CL2013003214A1 (es) Formulacion estable que comprende al menos un anticuerpo monoclonal que se une especificamente a pcsk9, un tampon, un surfactante y al menos un estabilizador; y su uso para tratar o prevenir enfermedades relacionadas con el colesterol.
ECSP13012724A (es) Anticuerpos para el receptor de la barrera hematoencefálica de baja afinidad y sus usos
UA109931C2 (xx) Піримідинциклогексильні модулятори глюкокортикоїдних рецепторів
EA201491161A1 (ru) Фторированные модуляторы рецепторов эстрогенов и их применение
EA201270815A1 (ru) Модуляторы рецепторов эстрогена и их применение
UY30573A1 (es) N-(1-hetaril-piperidin-4-il)-(het)arilamidas como moduladores del receptor ep2
BR112017011234A2 (pt) anticorpos contra receptor da barreira hematoencefálica e métodos de uso
GT201300122A (es) Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano
UY34486A (es) Anticuerpos dirigidos al receptor del factor de crecimiento epidérmico 3 (her3) dirigidos contra el dominio ii del her3
UA113879C2 (xx) ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ